Back to Results

Appili Therapeutics Inc (APLIF)

Appili Therapeutics Inc is a biopharmaceutical company focused on developing and acquiring medicines for infectious diseases with unmet medical needs in Canada. Its anti-infective pipeline includes ATI-1501, a taste-masked oral reformulation of metronidazole designed for anaerobic bacterial, protozoal, and parasitic infections; ATI-1801, a topical paromomycin formulation being developed for cutaneous leishmaniasis; and ATI-1701, a live-attenuated vaccine candidate for francisella tularensis. The company was incorporated in 2015 and is headquartered in Halifax, Canada. Appili Therapeutics shares trade as common stock on OTC Markets.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Overall Financial Health Dividend Yield Next Earnings Date Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
OTC-APLI.F
$0.013
26.0% Upside
Undervalued
Not available
Not available
Fair
0.0%
November 12, 2026
5.5x
941.056 K
10.698 M
86.0%
89.1%
-320.3
29.2%
Valuation • Fair Value

Appili Therapeutics Inc (OTC-APLI.F) Fair Value by Valuation Model

Review the available estimates for Appili Therapeutics Inc (OTC-APLI.F), including Comps Fair Value.

Primary Valuation Read

Fair Value

$0.013

Estimated upside of 26.0% versus the current market price.

Fair Value Confidence

Low

Confidence level for the primary fair value estimate.

Comps Fair Value

$0.013

Comparable-company valuation reference.

Analyst Price Target

Not available

Data is currently unavailable.

How to read these valuation models

Use the 3 available valuation references for Appili Therapeutics Inc (OTC-APLI.F) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for Appili Therapeutics Inc (OTC-APLI.F)

Review the profitability and growth indicators currently supported by the latest data.

Revenue

255.287 K

Current operating scale indicator.

Revenue Forecast

32.018 M

Forward revenue estimate.

EBITDA

-4.604 M

Current operating profitability reference.

EBITDA Forecast

22.848 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Appili Therapeutics Inc (OTC-APLI.F) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Appili Therapeutics Inc (OTC-APLI.F)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Fair

Mixed or neutral financial-health read.

Piotroski Score

2

Weak quality score that deserves closer review.

Altman Z-Score

-320.3

Lower score that deserves closer risk review.

FCF / Net Income

29.2%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Appili Therapeutics Inc (OTC-APLI.F). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Appili Therapeutics Inc (OTC-APLI.F)

Track the upcoming dates and dividend metrics currently supported by the latest data.

Next Earnings Date

November 12, 2026

Days to Earnings

51

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

This section helps investors track time-sensitive items for Appili Therapeutics Inc (OTC-APLI.F), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Technical Outlook

Technical Signals by Time Frame

Review the technical signals currently available for this stock across supported time frames.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Neutral

The 15-minute technical read for Appili Therapeutics Inc (OTC-APLI.F) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Buy

The 1-hour technical read for Appili Therapeutics Inc (OTC-APLI.F) is currently Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Neutral

The daily technical read for Appili Therapeutics Inc (OTC-APLI.F) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for Appili Therapeutics Inc (OTC-APLI.F) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for Appili Therapeutics Inc (OTC-APLI.F) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

FAQ • Fast Investor Answers

Appili Therapeutics Inc (OTC-APLI.F) Stock FAQ

Data-supported answers about Appili Therapeutics Inc (OTC-APLI.F), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$0.013
Estimated upside 26.0%
Valuation Rating
Undervalued
Estimated upside of 26.0%
Financial Health
Fair
Current financial-health read

The current fair value estimate for Appili Therapeutics Inc (OTC-APLI.F) is $0.013. This implies an estimated upside of 26.0% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 26.0% versus the current market price.

The current financial health read for Appili Therapeutics Inc (OTC-APLI.F) is Fair. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Appili Therapeutics Inc (OTC-APLI.F) is November 12, 2026.

The latest available data indicates no current dividend yield for Appili Therapeutics Inc (OTC-APLI.F).

The current market capitalization listed for Appili Therapeutics Inc is 941.056 K.

The current enterprise value listed for Appili Therapeutics Inc is 10.698 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Appili Therapeutics Inc is OTC-APLI.F, and the stock is listed on OTC Markets.

Appili Therapeutics Inc (OTC-APLI.F) is listed on OTC Markets.

The current debt-to-total-capital ratio listed for Appili Therapeutics Inc is 86.0%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Appili Therapeutics Inc is 89.1%. Free float helps investors understand how much of the share base is available for public trading.

Similar Pharmaceuticals Stocks View more on OTC Markets

Comparable companies from the same industry, limited to one security per issuer.

LLY NYSE Eli Lilly and Company Fair Value Fair Market Cap 1,043 B
JNJ NYSE Johnson & Johnson Fair Value Fair Market Cap 648.7 B
MRK NYSE Merck & Company Inc Fair Value Fair Market Cap 372.3 B
NVS NYSE Novartis AG ADR Fair Value Fair Market Cap 269.8 B
NVO NYSE Novo Nordisk A/S Fair Value Bargain Market Cap 175.3 B
PFE NYSE Pfizer Inc Fair Value Fair Market Cap 159.2 B
BMY NYSE Bristol-Myers Squibb Company Fair Value Fair Market Cap 127.2 B
SNY NASDAQ Sanofi ADR Fair Value Undervalued Market Cap 102 B
GSK NYSE GSK plc DRC Fair Value Undervalued Market Cap 101.9 B
TAK NYSE Takeda Pharmaceutical Co Ltd ADR Fair Value Fair Market Cap 60.536 B
TEVA NYSE Teva Pharma Industries Ltd ADR Fair Value Fair Market Cap 46.053 B
HLN NYSE HALEON PLC ADR Fair Value Fair Market Cap 40.268 B
RPRX NASDAQ Royalty Pharma Plc Fair Value Fair Market Cap 33.639 B
ZTS NYSE Zoetis Inc Fair Value Bargain Market Cap 30.107 B
VTRS NASDAQ Viatris Inc Fair Value Undervalued Market Cap 19.733 B
JAZZ NASDAQ Jazz Pharmaceuticals PLC Fair Value Fair Market Cap 15.616 B
CORT NASDAQ Corcept Therapeutics Incorporated Fair Value Overvalued Market Cap 12.702 B
ELAN NYSE Elanco Animal Health Fair Value Fair Market Cap 11.456 B
AXSM NASDAQ Axsome Therapeutics Inc Fair Value Fair Market Cap 10.639 B
RDY NYSE Dr. Reddy’s Laboratories Ltd ADR Fair Value Fair Market Cap 10.564 B